lonatra 2,3 %+1,75 mmol/l peritonealdialysevæske
fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske - 2,3 %+1,75 mmol/l
lonatra 4,25 %+1,25 mmol/l peritonealdialysevæske
fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat opløsning, natriumchlorid - peritonealdialysevæske - 4,25 %+1,25 mmol/l
lonatra 4,25 %+1,75 mmol/l peritonealdialysevæske
fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske - 4,25 %+1,75 mmol/l
multibic 3 mmol/l kalium hæmodialyse-/hæmofiltreringsvæske
fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - hæmodialyse-/hæmofiltreringsvæske - 3 mmol/l
infusolec infusionsvæske, opløsning
dechra regulatory b.v. - calciumchloriddihydrat, kaliumchlorid, natriumchlorid, natriumlactat - infusionsvæske, opløsning - hest, hund, kat, kvæg
gelaspan 40 mg/ml infusionsvæske, opløsning
orifarm a/s - calciumchloriddihydrat, gelatinepolysuccinat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 40 mg/ml
benelyte 6,429+0,298+0,147+0,203+4,082+11,0 mg/ml infusionsvæske, opløsning
fresenius kabi ab - calciumchloriddihydrat, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 6,429+0,298+0,147+0,203+4,082+11,0 mg/ml
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
renagel
sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle andre terapeutiske produkter - renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.